Scope: Create a soft tissue ablation system for targeted prostate cancer treatment.

 

Challenge: Multiple catheters guided into a small location, with laser energy for ablation. Enable real-time active cooling, thermal monitoring, and laser control in the O.R.

 

Outcome: Idea to 510(k) in two years. 100% success in patient studies – improved quality of life and no rehabilitation needed after treatment.

 

 

The Avenda system is the first FDA-approved prostate cancer treatment in 40 years.